

---

## D I R E C T I O N S

---

# THE NATIONAL HEALTH SERVICE ACT 2006

## The Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 3) Directions 2019

The Secretary of State gives the following Directions in exercise of the powers conferred by sections 127, 128, 272(7) and (8) and 273(1) of the National Health Service Act 2006(a).

### Citation, commencement, application and interpretation

1.—(1) These Directions may be cited as the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 3) Directions 2019.

(2) These Directions, apart from directions 4 and 5, come into force on 1st October 2019.

(3) Direction 4 comes into force on 1st April 2020.

(4) Direction 5 comes into force on 1st April 2021.

(5) These Directions apply in relation to England.

(6) In these Directions, “the 2013 Directions” means the Pharmaceutical Services (Advanced and Enhanced Services) (England) Directions 2013(b).

### Amendment of direction 2 of the 2013 Directions

2.—(1) Direction 2 of the 2013 Directions (interpretation) is amended as follows.

(2) In the definition of “NHS 111 service” for “medical helpline” substitute “telephone and online”.

### Amendment of direction 5 of the 2013 Directions

3.—(1) Direction 5 of the 2013 Directions(c) (MUR services: ongoing conditions of arrangements) is amended as follows.

(2) In paragraph (1)—

---

(a) 2006 c. 41. Section 127 has been amended by the Health and Social Care Act 2012 (c. 7) (“the 2012 Act”), Schedule 4, paragraph 64; and section 128 has been amended by the 2012 Act, Schedule 4, paragraph 65.

(b) Signed on 12th March 2013, and amended by: the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2013, signed on 16th September 2013; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2013, signed on 6th December 2013, which also revoked the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2013; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2014, signed on 12th March 2014; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2014, signed on 5th December 2014; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2015, signed on 15th September 2015; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2016, signed on 30th August 2016; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No.2) Directions 2016, signed on 30th November 2016; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2017, signed on 29th August 2017; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2018, signed on 8th March 2018; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2018, signed on 31st August 2018; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2019, signed on 13th March 2019; and the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2019, signed on 22nd August 2019.

(c) Relevant amendments were made by the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2019, signed on 13th March 2019.

(a) for sub-paragraph (d) substitute—

“(d) no more than 250 service consultations are carried out in the period beginning on 1st April 2019 and ending on 31st March 2020 (no more than 200 having been carried out before 1st October 2019), whether at an acceptable location or by telephone;” and

(b) for sub-paragraph (g) substitute—

“(g) at least 70% of the MUR service consultations carried out—

(i) in the period beginning on 1st April 2019 and ending at the end of 30th September 2019 were carried out with patients who were in one or more of the national target groups set out in Schedule 1, as in force on 30th September 2019, and

(ii) in the period beginning on 1st October 2019 and ending at the end of 31st March 2020, and in the 2020/21 financial year, are to be carried out with patients who are in one or more of the national target groups set out in Schedule 1;”.

#### **Medicines Use Review provision in the financial year beginning on 1st April 2020**

4.—(1) Direction 5 of the 2013 Directions (MUR services: ongoing conditions of arrangements) is amended as follows.

(2) In paragraph (1), for sub-paragraph (d) substitute—

“(d) no more than 100 service consultations are carried out in the period beginning on 1st April 2020 and ending at the end of 31st March 2021, whether at an acceptable location or by telephone;”.

#### **Ending of Medicines Use Review provision at the end of 31st March 2021**

5.—(1) Directions 4 and 5 of the 2013 Directions (MUR services – general matters and preconditions for making arrangements, and on-going conditions for arrangements) are revoked.

(2) Schedule 1 to the 2013 Directions (National Target Groups for MUR services) is revoked.

(3) In direction 2(1) of the 2013 Directions (interpretation), omit the definitions of “MUR certificate” and “MUR services”.

(4) Directions 2 and 4 of the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2014, signed on 5th December 2014, are revoked.

(5) The Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2019, signed on 13th March 2019, are revoked.

#### **Amendment of directions 7C and 7D of the 2013 Directions**

6.—(1) In direction 7C of the 2013 Directions(a) (NHS Urgent Medicine Supply Advanced Service pilot scheme – general matters and preconditions to making arrangements), in paragraph (1), for “30 September 2019” substitute “28 October 2019”.

(2) In direction 7D of the 2013 Directions(b) (NHS Urgent Medicine Supply Advanced Service pilot scheme – ongoing conditions of arrangements), in paragraph (12), for “30th September 2019” substitute “28th October 2019”.

---

(a) A relevant amendment was made by the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2019, signed on 13th March 2019.

(b) A relevant amendment was made by the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2019, signed on 13th March 2019.

## Substitution of Schedules 1 and 2 to the 2013 Directions

7. For Schedules 1 and 2 to the 2013 Directions(a) (National Target Groups for MUR services, and NMS medicines) substitute the following Schedules—

### “SCHEDULE 1

Direction 5(1)(g)

#### National Target Groups for MUR services

1. Patients taking a high risk medicine, and for these purposes, a “high risk medicine” is a medicine which is of one of the descriptions referenced in the table in this paragraph and is on the list of medicines that are high risk medicines for the purposes of MUR services that is published by the NHS BSA on its website(b) and amended from time to time—

<i>Descriptors</i>
NSAIDs
Anticoagulants (including low molecular weight heparin)
Antiplatelets
Diuretics

2. Patients recently (that is, within the previous 8 weeks) discharged from hospital who have had changes made to the drugs they are taking while they were in hospital (it is anticipated that patients in this target group will generally be offered an MUR services consultation within 4 weeks of discharge).

### SCHEDULE 2

Direction 7(1)(e)

#### NMS medicines

1. For the purposes of these Directions, an “NMS medicine” is a drug which is of one of the descriptions referenced in the tables in this paragraph (which are headed with the conditions or therapies to which they relate) and is on the list of medicines that are NMS medicines that is published by the NHS BSA on its website(c) and amended from time to time—

#### *Asthma and Chronic Obstructive Pulmonary Disease*

<i>Descriptors</i>
Adrenoceptor agonists
Antimuscarinic bronchodilators
Theophylline
Compound bronchodilator preparations
Corticosteroids
Cromoglicate and related therapy, leukotriene receptor antagonists and phosphodiesterase type-4 inhibitors

#### *Type 2 Diabetes*

- 
- (a) Schedule 1 has been amended by the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2014, signed on 5th December 2014.
- (b) The current list is available at <https://www.nhsbsa.nhs.uk/mur-nms-druglists>.
- (c) The current list is available at <https://www.nhsbsa.nhs.uk/mur-nms-druglists>.

<i>Descriptors</i>
Short acting insulins (where the pharmacist can determine that the medicine has been newly prescribed for a patient with Type 2 diabetes)
Intermediate and long acting insulins (where the pharmacist can determine that the medicine has been newly prescribed for a patient with Type 2 diabetes)
Antidiabetic drugs

*Antiplatelet/Anticoagulant therapy*


<i>Descriptors</i>
Oral anticoagulants
Antiplatelet drugs

*Hypertension*

<i>Descriptors</i>
Thiazides and related diuretics
Beta-adrenoceptor blocking drugs (where the pharmacist can determine that the medicine has been newly prescribed for a patient with hypertension)
Vasodilator antihypertensive drugs
Centrally acting antihypertensive drugs
Alpha-adrenoceptor blocking drugs (where the pharmacist can determine that the medicine has been newly prescribed for a patient with hypertension)
Drugs affecting the renin-angiotensin system (where the pharmacist can determine that the medicine has been newly prescribed for a patient with hypertension)
Calcium-channel blockers (where the pharmacist can determine that the medicine has been newly prescribed for a patient with hypertension)

”

Signed by authority of the Secretary of State for Health and Social Care



11th September 2019

*Jeannette Howe*  
Head of Pharmacy  
Department of Health and Social Care